Wang Xiang, Xi Wei-Chun, Wang Fang
Department of Cardiology, Shanghai First People's Hospital, Affiliated Shanghai Jiaotong University, Shanghai, 200080, China.
Biotechnol Lett. 2014 Nov;36(11):2163-8. doi: 10.1007/s10529-014-1589-z. Epub 2014 Jun 30.
The efficacy of post-percutaneous coronary intervention (PCI) intracoronary injection with bone marrow mesenchymal stem cells (BMSCs) in patients with acute myocardial infarction (AMI) remains controversial. Here, 58 patients with AMI undergoing PCI were randomly divided into two groups: BMSC and control groups. Autologous BSMCs were then generated in vitro from the BMSC patients. After transplantation, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimensions (LVDd), and infarct size (IS) were evaluated in both groups. LVEF, LVDd, and IS improved after BMSC transplantation but the changes were not significantly different from those in the controls. The number of adverse events and rehospitalization rates after 1 month were significantly higher in the control group than in the BMSC group. BMSC transplantation thus benefits patients by decreasing the number of adverse events and reducing the rehospitalization rate in the early stages following PCI.
经皮冠状动脉介入治疗（PCI）后冠状动脉内注射骨髓间充质干细胞（BMSC）对急性心肌梗死（AMI）患者的疗效仍存在争议。在此，58例接受PCI的AMI患者被随机分为两组：BMSC组和对照组。然后从BMSC组患者体外生成自体BMSC。移植后，对两组患者的左心室射血分数（LVEF）、左心室舒张末期内径（LVDd）和梗死面积（IS）进行评估。BMSC移植后LVEF、LVDd和IS有所改善，但与对照组的变化无显著差异。对照组1个月后的不良事件数量和再住院率显著高于BMSC组。因此，BMSC移植可通过减少PCI后早期的不良事件数量和降低再住院率而使患者受益。
